Research programme: biosimilars - AvesthaGen

Drug Profile

Research programme: biosimilars - AvesthaGen


Latest Information Update: 27 May 2016

Price : $50

At a glance

  • Originator Avesthagen
  • Class Recombinant proteins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; Cancer; Cardiovascular disorders

Most Recent Events

  • 23 May 2016 Kemwell Biopharma has been acquired by Recipharm
  • 03 Apr 2012 Preclinical development in Autoimmune disorders, Cancer and Cardiovascular disorders is ongoing in India
  • 16 May 2004 Preclinical trials in Autoimmune disorders in India (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top